Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older. Novavax's product — Nuvaxovid XBB.1.5 Omicron subvariant COVID-19 vaccine — uses a ...

Novavax's vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Canada has detected its first presumptive case of H5 bird flu in a person, a teenager in the western province of British ...

Under terms of the deal, the company and the UKHSA agreed to settle the outstanding amount under dispute related to upfront ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the ...

Novavax’s vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...